Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
April 25, 2022 10:22 AM 2 min read

You Ask, We Analyze: What To Watch For In Clarus Therapeutics Stock Following Last Week's Surge

by Melanie Schaffer Benzinga Editor
Follow
FlipboardIcon version of the Flipboard logo

On Sunday evening, Benzinga asked its followers on Twitter what they’re buying at the open on Monday. From the replies Benzinga selected one ticker for technical analysis.

@Williamdontkno1, @Natronrz and @getsumgetright are buying Clarus Therapeutics Holdings, Inc (NASDAQ:CRXT).

On April 19, Clarus announced it would present new data for its testosterone replacement therapy drug Jatenzo on Saturday at the Androgen Society 4th Annual Meeting. The stock surged 207% between April 19 and April 20 before topping out $3.94 and retracing about 54% to reach a low of $1.78 on Friday.

Due to Clarus’ underlying statistics, the stock has qualities that make it susceptible to high volatility and also make it a good candidate for a short squeeze. Clarus has just 1.17 million shares available for trading, of which 68.76% are held by institutions and insiders. Stocks with small floats are inherently volatile because when demand increases, it becomes difficult for buyers to be matched with sellers.

The percentage of Clarus’ float held short also increased drastically in March. As of the end of that month, 744,480 shares were held short compared to just 45,220 shares the month prior.

Volatility can move stocks both ways and due to this, Clarus can swing wildly in either direction and defy some technical indicators. A period of consolidation always follows high volatility, however, and Clarus looks set to enter into a period of stability in the short-term.

Want direct analysis? Find me in the BZ Pro lounge! Click here for a free trial.

The Clarus Chart: Clarus was trading down over 45% at one point in the premarket after closing Friday’s trading session down about 12%. The stock experienced a volume climax on April 20, which exhausted buyers and resulted in a high level of fear selling.

Technical traders may have seen the volume climax taking place because at 10:30 a.m., Clarus’ trading volume was measuring in at the highest level the stock had ever experienced. The high volume also caused Clarus’ relative strength index (RSI) to reach 71% on the daily chart, which set the stock into overbought territory.

There is a gap on Clarus’ chart between $1.50 and $1.72, which is below Friday’s closing price but above Monday’s premarket price. Gaps on charts are about 90% likely to fill, which indicates Clarus will trade into the empty range at some point in the future.

Bullish traders will want to watch for the stock to settle into a consolidation period of lower-than-average volume, which could indicate the stock is running out of sellers and then for big bullish volume to come in and push the stock back up into the gap.

Bearish traders want to see bearish momentum drive the stock back down under the psychologically important $1 level, which will make the area heavy resistance.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Penny StocksTechnicalsMoversTrading Ideas
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...